Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defensin-mimetic

Related Keywords

United States ,Leo Ehrlich ,Centers For Disease ,Innovation Pharmaceuticals Inc ,Us Department Of Health ,Human Services ,National Institutes Of Health ,National Institute Of Allergy ,World Health Organization ,Exchange Commission ,Strategic National Stockpile ,Innovation Pharmaceuticals ,Public Health Emergency Of International Concern ,National Institutes ,National Institute ,Infectious Diseases ,Chief Executive Officer ,Emergency Dashboard ,Disease Control ,Public Health Emergency ,International Concern ,Expanded Access ,Vaccinia Virus ,Eczema Vaccinatum ,Future Considerations ,Looking Statements ,Private Securities Litigation Reform Act ,Stingray System ,Innovation ,Pharmaceuticals ,Nnounces ,Siaid ,Ffiliated ,Researchers ,Valuate ,Brilacidin ,Treatment ,Potential ,Against ,Monkeypox ,